Elevated IgM against Nε-(Carboxyethyl)lysine-modified Apolipoprotein A1 peptide 141–147 in Taiwanese with Alzheimer's disease
Lin CY, Sheu JJ, Tsai IS, Wang ST, Yang LY, Hsu IU, Chang HW, Lee HM, Kao SH, Lee CK, Chen CH, Lin YF. Elevated IgM against Nε-(Carboxyethyl)lysine-modified Apolipoprotein A1 peptide 141–147 in Taiwanese with Alzheimer's disease. Clinical Biochemistry 2018, 56: 75-82. PMID: 29680706, DOI: 10.1016/j.clinbiochem.2018.04.009.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAlzheimer DiseaseAntibody SpecificityApolipoprotein A-IAutoantibodiesAutoimmunityBiomarkersCase-Control StudiesEnzyme-Linked Immunosorbent AssayFemaleGlycation End Products, AdvancedHumansImmunoglobulin MLysineMalePeptide FragmentsProtein Processing, Post-TranslationalPsychiatric Status Rating ScalesROC CurveTaiwanUp-RegulationConceptsAdvanced glycation end productsSpecific advanced glycation end productsAlzheimer's diseaseMini-Mental State Examination scoreMental State Examination scoreEarly AD markersEarly AD pathologyState Examination scoreEarly disease statesGlycation end productsRelated autoantibodiesAD markersIgM levelsAD pathologyElevated IgMAD seraAD patientsDisease progressionAD biomarkersApolipoprotein A1IgMAutoantibodiesApoA1Serum samplesWestern blotting